|
1
|
Lin X, Liao Y, Xie J, Liu S, Su L and Zou
H: Op18/stathmin is involved in the resistance of taxol among
different epithelial carcinoma cell lines. Cancer Biother
Radiopharm. 29:376–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yip YY, Yeap YY, Bogoyevitch MA and Ng DC:
Differences in c-Jun N-terminal kinase recognition and
phosphorylation of closely related stathmin-family members. Biochem
Biophys Res Commun. 446:248–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Machado-Neto JA, Lazarini M, Favaro P, de
Melo Campos P, Scopim-Ribeiro R, Franchi Junior GC, Nowill AE, Lima
PR, Costa FF, Benichou S, et al: ANKHD1 silencing inhibits Stathmin
1 activity, cell proliferation and migration of leukemia cells.
Biochim Biophys Acta. 1853:583–593. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Machado-Neto JA, de Melo Campos P, Favaro
P, Favaro P, Lazarini M, Lorand-Metze I, Costa FF, Olalla Saad ST
and Traina F: Stathmin 1 is involved in the highly proliferative
phenotype of high-risk myelodysplastic syndromes and acute leukemia
cells. Leuk Res. 38:251–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nemunaitis J: Stathmin 1: A protein with
many tasks. New biomarker and potential target in cancer. Expert
Opin Ther Targets. 16:631–634. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Johnsen JI, Aurelio ON, Kwaja Z, Jörgensen
GE, Pellegata NS, Plattner R, Stanbridge EJ and Cajot JF:
p53-mediated negative regulation of stathmin/Op18 expression is
associated with G2/M cell-cycle arrest. Int J Cancer.
88:685–691. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ke B, Wu LL, Liu N, Zhang RP, Wang CL and
Liang H: Overexpression of stathmin 1 is associated with poor
prognosis of patients with gastric cancer. Tumour Biol.
34:3137–3145. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Watanabe A, Suzuki H, Yokobori T,
Tsukagoshi M, Altan B, Kubo N, Suzuki S, Araki K, Wada S,
Kashiwabara K, et al: Stathmin 1 regulates p27 expression,
proliferation and drug resistance, resulting in poor clinical
prognosis in cholangiocarcinoma. Cancer Sci. 105:690–696. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Long D, Yu T, Chen X, Liao Y and Lin X:
RNAi targeting STMN alleviates the resistance to taxol and
collectively contributes to down regulate the malignancy of NSCLC
cells in vitro and in vivo. Cell Biol Toxicol. 34:7–21. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee EH, Kim SS and Seo SR: Pyrrolidine
dithiocarbamate (PDTC) inhibits inflammatory signaling via
expression of regulator of calcineurin activity 1 (RCAN1):
Anti-inflammatory mechanism of PDTC through RCAN1 induction.
Biochem Pharmacol. 143:107–117. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ko EY, Cho SH, Kwon SH, Eom CY, Jeong MS,
Lee W, Kim SY, Heo SJ, Ahn G, Lee KP, et al: The roles of NF-kappaB
and ROS in regulation of pro-inflammatory mediators of inflammation
induction in LPS-stimulated zebrafish embryos. Fish Shellfish
Immunol. 68:525–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin X, Yu T, Zhang L, Chen S, Chen X, Liao
Y, Long D and Shen F: Silencing Op18/stathmin by RNA interference
promotes the sensitivity of nasopharyngeal carcinoma cells to taxol
and high-grade differentiation of xenografted tumours in nude mice.
Basic Clin Pharmacol Toxicol. 119:611–620. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cheng SB and Sharma S: Interleukin-10: A
pleiotropic regulator in pregnancy. Am J Reprod immunol.
73:487–500. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heine G, Drozdenko G, Grun JR, Chang HD,
Radbruch A and Worm M: Autocrine IL-10 promotes human B-cell
differentiation into IgM- or IgG-secreting plasmablasts. Eur J
Immunol. 44:1615–1621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ledeboer A, Breve JJ, Wierinckx A, van der
Jagt S, Bristow AF, Leysen JE, Tilders FJ and Van Dam AM:
Expression and regulation of interleukin-10 and interleukin-10
receptor in rat astroglial and microglial cells. Eur J Neurosci.
16:1175–1185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rodriguez JA, Galeano L, Palacios DM,
Gómez C, Serrano ML, Bravo MM and Combita AL: Altered HLA class I
and HLA-G expression is associated with IL-10 expression in
patients with cervical cancer. Pathobiology. 79:72–83. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sakamaki K, Imai K, Tomii K and Miller DJ:
Evolutionary analyses of caspase-8 and its paralogs: Deep origins
of the apoptotic signaling pathways. Bioessays. 37:767–776. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Itakura E, Huang RR, Wen DR, Paul E,
Wunsch PH and Cochran AJ: IL-10 expression by primary tumor cells
correlates with melanoma progression from radial to vertical growth
phase and development of metastatic competence. Mod Pathol.
24:801–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mahipal A, Terai M, Berd D, Chervoneva I,
Patel K, Mastrangelo MJ and Sato T: Tumor-derived interleukin-10 as
a prognostic factor in stage III patients undergoing adjuvant
treatment with an autologous melanoma cell vaccine. Cancer Immunol
Immunother. 60:1039–1045. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barrera L, Montesservín E, Barrera A,
Ramírez-Tirado LA, Salinas-Parra F, Bañales-Méndez JL,
Sandoval-Ríos M and Arrieta Ó: Cytokine profile determined by
data-mining analysis set into clusters of non-small-cell lung
cancer patients according to prognosis. Ann Oncol. 26:428–435.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gupta M, Han JJ, Stenson M, Maurer M,
Wellik L, Hu G, Ziesmer S, Dogan A and Witzig TE: Elevated serum
IL-10 levels in diffuse large B-cell lymphoma: A mechanism of
aberrant JAK2 activation. Blood. 119:2844–2853. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lech-Maranda E, Baseggio L, Bienvenu J,
Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B and Salles G:
Interleukin-10 gene promoter polymorphisms influence the clinical
outcome of diffuse large B-cell lymphoma. Blood. 103:3529–3534.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Danoch H, Kalechman Y, Albeck M, Longo DL
and Sredni B: Sensitizing B- and T-cell lymphoma cells to
paclitaxel/abraxane-induced death by AS101 via inhibition of the
VLA-4-IL10-survivin axis. Mol Cancer Res. 13:411–422. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bermudez-Morales VH, Peralta-Zaragoza O,
Alcocer-Gonzalez JM, Moreno J and Madrid-Marina V: IL-10 expression
is regulated by HPV E2 protein in cervical cancer cells. Mol Med
Rep. 4:369–375. 2011.PubMed/NCBI
|
|
25
|
Lin X, Tang M, Tao Y, Li L, Liu S, Guo L,
Li Z, Ma X, Xu J and Cao Y: Epstein-Barr virus-encoded LMP1
triggers regulation of the ERK-mediated Op18/stathmin signaling
pathway in association with cell cycle. Cancer Sci. 103:993–999.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lin X, Liu S, Luo X, Ma X, Guo L, Li L, Li
Z, Tao Y and Cao Y: EBV-encoded LMP1 regulates Op18/stathmin
signaling pathway by cdc2 mediation in nasopharyngeal carcinoma
cells. Int J Cancer. 124:1020–1027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin X, Liao Y, Chen X, Long D, Yu T and
Shen F: Regulation of oncoprotein 18/stathmin signaling by ERK
concerns the resistance to taxol in nonsmall cell lung cancer
cells. Cancer Biother Radiopharm. 31:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen X, Liao Y, Long D, Yu T, Shen F and
Lin X: The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the
cytotoxic effects of taxol through Op18/stathmin in non-small cell
lung cancer cells in vitro. Int J Mol Med. 40:235–242. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hoesel B and Schmid JA: The complexity of
NF-kappaB signaling in inflammation and cancer. Mol Cancer.
12:862013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen JY, He XX, Ma C, Wu XM, Wan XL, Xing
ZK, Pei QQ, Dong XP, Liu DX, Xiong WC, et al: Netrin-1 promotes
glioma growth by activating NF-kappaB via UNC5A. Sci Rep.
7:54542017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lu Y, Liu C, Cheng H, Xu Y, Jiang J, Xu J,
Long J, Liu L and Yu X: Stathmin, interacting with Nf-kappaB,
promotes tumor growth and predicts poor prognosis of pancreatic
cancer. Curr Mol Med. 14:328–339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang T, Shi F, Wang J, Liu Z and Su J:
Kallistatin Suppresses cell proliferation and invasion and promotes
apoptosis in cervical cancer through blocking NF-kappaB signaling.
Oncol Res. 25:809–817. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mittal SK and Roche PA: Suppression of
antigen presentation by IL-10. Curr Opin Immunol. 34:22–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tanikawa T, Wilke CM, Kryczek I, Chen GY,
Kao J, Núñez G and Zou W: Interleukin-10 ablation promotes tumor
development, growth, and metastasis. Cancer Res. 72:420–429. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rizzuti D, Ang M, Sokollik C, Wu T,
Abdullah M, Greenfield L, Fattouh R, Reardon C, Tang M, Diao J, et
al: Helicobacter pylori inhibits dendritic cell maturation via
interleukin-10-mediated activation of the signal transducer and
activator of transcription 3 pathway. J Innate Immun. 7:199–211.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang C, He L, He P, Liu Y, Wang W, He Y,
Du Y and Gao F: Increased drug resistance in breast cancer by
tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling
pathway. Med Oncol. 32:3522015. View Article : Google Scholar : PubMed/NCBI
|
